Development
Lantern Pharma Inc.
LTRN
$3.32
-$0.11-3.21%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.31M | 1.63M | 1.73M | 1.57M | 1.44M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.52M | 5.19M | 4.29M | 3.83M | 2.15M |
| Operating Income | -3.52M | -5.19M | -4.29M | -3.83M | -2.15M |
| Income Before Tax | -3.16M | -4.75M | -3.87M | -3.38M | -2.26M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.16M | -4.75M | -3.87M | -3.38M | -2.26M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.16M | -4.75M | -3.87M | -3.38M | -2.26M |
| EBIT | -3.52M | -5.19M | -4.29M | -3.83M | -2.15M |
| EBITDA | -3.52M | -5.19M | -4.28M | -3.82M | -2.14M |
| EPS Basic | -0.29 | -0.44 | -0.36 | -0.31 | -0.21 |
| Normalized Basic EPS | -0.18 | -0.27 | -0.22 | -0.19 | -0.13 |
| EPS Diluted | -0.29 | -0.44 | -0.36 | -0.31 | -0.21 |
| Normalized Diluted EPS | -0.18 | -0.27 | -0.22 | -0.19 | -0.13 |
| Average Basic Shares Outstanding | 10.86M | 10.86M | 10.86M | 10.86M | 10.84M |
| Average Diluted Shares Outstanding | 10.86M | 10.86M | 10.86M | 10.86M | 10.84M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |